Last reviewed · How we verify
HBOT
At a glance
| Generic name | HBOT |
|---|---|
| Also known as | HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments |
| Sponsor | Assaf-Harofeh Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study (PHASE4)
- Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions
- Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (NA)
- Hyperbaric Oxygen Therapy in Complex Regional Pain Syndrome (NA)
- Long Lasting Effect of Hyperbaric Oxygen Therapy on Cognitive Function in Traumatic Brain Injury Patients
- Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition (NA)
- Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression (NA)
- Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBOT CI brief — competitive landscape report
- HBOT updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI